Clinical Trials Slated for Treatment That Shrinks All Tumors Tested

Last year, a PNAS study showed that the surfaces of many tumor cells have a protein called CD47, which protects them from the immune system. But when these tumors are treated with a drug that inhibits CD47, they get attacked by immune system cells. The researchers transplanted seven kinds of human tumors into mice and treated them with the CD47-targeting drug. All of the tumors—bladder, brain, breast, colon, liver, ovary, and prostate—shrank or disappeared, which kept them from spreading. Now, the research will progress to clinical trials, thanks to a $20 million grant from the California Institute for Regenerative Medicine. CD47 was originally found on leukemia and lymphoma cells; the initial trial will target the stem cells that perpetuate acute myeloid leukemia. This cancer of the blood and bone marrow is fatal within months if untreated, and the 5-year survival rate is only 30% to 40%, even with aggressive treatments including chemotherapy and bone marrow transplants.


Clinical Trials Slated for Treatment That Shrinks All Tumors Tested

Last year, a PNAS study showed that the surfaces of many tumor cells have a protein called CD47, which protects them from the immune system. But when these tumors are treated with a drug that inhibits CD47, they get attacked by immune system cells. The researchers transplanted seven kinds of human tumors into mice and treated them with the CD47-targeting drug. All of the tumors—bladder, brain, breast, colon, liver, ovary, and prostate—shrank or disappeared, which kept them from spreading. Now, the research will progress to clinical trials, thanks to a $20 million grant from the California Institute for Regenerative Medicine. CD47 was originally found on leukemia and lymphoma cells; the initial trial will target the stem cells that perpetuate acute myeloid leukemia. This cancer of the blood and bone marrow is fatal within months if untreated, and the 5-year survival rate is only 30% to 40%, even with aggressive treatments including chemotherapy and bone marrow transplants.


Clinical Trials Slated for Treatment That Shrinks All Tumors Tested

Last year, a PNAS study showed that the surfaces of many tumor cells have a protein called CD47, which protects them from the immune system. But when these tumors are treated with a drug that inhibits CD47, they get attacked by immune system cells. The researchers transplanted seven kinds of human tumors into mice and treated them with the CD47-targeting drug. All of the tumors—bladder, brain, breast, colon, liver, ovary, and prostate—shrank or disappeared, which kept them from spreading. Now, the research will progress to clinical trials, thanks to a $20 million grant from the California Institute for Regenerative Medicine. CD47 was originally found on leukemia and lymphoma cells; the initial trial will target the stem cells that perpetuate acute myeloid leukemia. This cancer of the blood and bone marrow is fatal within months if untreated, and the 5-year survival rate is only 30% to 40%, even with aggressive treatments including chemotherapy and bone marrow transplants.


U.S. Cancer Survivors Projected to Jump 30% over Next Decade

The number of cancer survivors in the U.S. will rise from 13.7 million today to 18.0 million in 2022, according to the American Association for Cancer Research. This increase will be driven by the aging population, with two-thirds of cancer survivors being age 65 years or older within 10 years. Today, women with breast cancer account for about one-fifth of survivors and men with prostate cancer account for another one-fifth, reflecting strides in diagnosis and treatment. Five-year survival rates are now nearly 89% for breast cancer and nearly 100% for prostate cancer. However, people with lung cancer account for just 3% of today’s survivors, underscoring the need for better ways of diagnosing and treating this illness.


Turning of COGS moves forward findings for hormonally mediated cancers

“The large-scale Collaborative Oncological Gene-environment Study (COGS) presents new findings that further characterize the genetic bases of breast, ovarian and prostate cancers. We summarize and provide insights into this collection of papers from COGS and discuss the implications of the results and future directions for such efforts.”


Lung cancer set to overtake breast cancer as the main cause of cancer deaths among European women

Lung cancer is likely to overtake breast cancer as the main cause of cancer death among European women by the middle of this decade, according to new research published in the cancer journal Annals of Oncology on February 13. In the UK and Poland it has already overtaken breast cancer as the main cause of cancer deaths in women.